Evidence map›Paper›PMID 37102920›Full record

ArticleGels (Basel, Switzerland)2023

Gel Formulations with an Echinocandin for Cutaneous Candidiasis: The Influence of Azone and Transcutol on Biopharmaceutical Features.

Noelia Pérez-González, Lupe Carolina Espinoza, María Rincón, Lilian Sosa, Mireia Mallandrich, Joaquim Suñer-Carbó, Nuria Bozal-de Febrer, Ana Cristina Calpena, Beatriz Clares-Naveros

Open access · goldAbstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Noelia Pérez-GonzálezDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University Campus of Cartuja, University of Granada, 18071 Granada, Spain.ORCID 0000-0001-6251-1752
Lupe Carolina EspinozaDepartamento de Química, Universidad Técnica Particular de Loja, Loja 1101608, Ecuador.ORCID 0000-0003-1486-5622
María RincónDepartament de Ciència de Materials i Química Física, Facultat de Química, Universitat de Barcelona (UB), C. Martí i Franquès 1-11, 08028 Barcelona, Spain.ORCID 0009-0002-9012-0008
Lilian SosaPharmaceutical Technology Research Group, Faculty of Chemical Sciences and Pharmacy, National Autonomous University of Honduras (UNAH), Tegucigalpa 11101, Honduras.
Mireia MallandrichInstitut de Nanociència i Nanotecnologia (IN2UB), Universitat de Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0001-9316-8459
Joaquim Suñer-CarbóInstitut de Nanociència i Nanotecnologia (IN2UB), Universitat de Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-9238-187X
Nuria Bozal-de FebrerDepartament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0001-5363-3125
Ana Cristina CalpenaInstitut de Nanociència i Nanotecnologia (IN2UB), Universitat de Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-4989-4821
Beatriz Clares-NaverosDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University Campus of Cartuja, University of Granada, 18071 Granada, Spain.ORCID 0000-0001-6126-7890
Institut de Nanociència i Nanotecnologia de la Universitat de BarcelonaUniversidad de Granada · ESNational Autonomous University of Honduras · HNUniversidad Técnica Particular de Loja · ECUniversitat de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caspofungin is a drug that is used for fungal infections that are difficult to treat, including invasive aspergillosis and candidemia, as well as other forms of invasive candidiasis. The aim of this study was to incorporate Azone in a caspofungin gel (CPF-AZ-gel) and compare it with a promoter-free caspofungin gel (CPF-gel). An in vitro release study using a polytetrafluoroethylene membrane and ex vivo permeation into human skin was adopted. The tolerability properties were confirmed by histological analysis, and an evaluation of the biomechanical properties of the skin was undertaken. Antimicrobial efficacy was determined against

Indexed as

Azonecandidiasiscaspofunginechinocandingelpermeation enhancer

Identifiers

PMID37102920
PMCPMC10138157
OpenAlexW4362665939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.